These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8857557)

  • 21. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
    Olesen OV; Linnet K
    Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the metabolic fate of M17055, a novel diuretic (6). Assessment for drug-drug interactions of M17055 in metabolism, distribution and excretion.
    Nakajima H; Nakanishi T; Naba H; Nakai K; Matsumoto S; Nagasawa K; Ida K; Ogihara T; Ohzawa N
    Xenobiotica; 2002 Dec; 32(12):1161-72. PubMed ID: 12593763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo modulation of CYP enzymes by quinidine and rifampin.
    Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
    Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human cytochrome P450s: selectivity and measurement in vivo.
    Smith DA; Abel SM; Hyland R; Jones BC
    Xenobiotica; 1998 Dec; 28(12):1095-128. PubMed ID: 9890156
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacogenetics and psychopharmacotherapy.
    Poolsup N; Li Wan Po A; Knight TL
    J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
    Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
    Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug metabolism and variability among patients in drug response.
    Wilkinson GR
    N Engl J Med; 2005 May; 352(21):2211-21. PubMed ID: 15917386
    [No Abstract]   [Full Text] [Related]  

  • 29. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
    Galetin A; Houston JB
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Supermix as an in vitro model of human liver microsomal drug metabolism.
    Venkatakrishnan K; Von Moltke LL; Greenblatt DJ
    Biopharm Drug Dispos; 2002 Jul; 23(5):183-90. PubMed ID: 12116049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions.
    Crespi CL; Penman BW
    Adv Pharmacol; 1997; 43():171-88. PubMed ID: 9342176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochromes P450 and metabolism of xenobiotics.
    Anzenbacher P; Anzenbacherová E
    Cell Mol Life Sci; 2001 May; 58(5-6):737-47. PubMed ID: 11437235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine.
    Niwa T; Sato R; Yabusaki Y; Ishibashi F; Katagiri M
    Xenobiotica; 1999 Feb; 29(2):187-93. PubMed ID: 10199594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
    Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
    Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human liver cytochrome P-450 and conjugating enzymes. Hungarian data.
    Vereczkey L; Jemnitz K; Monostory K
    Acta Physiol Hung; 1997-1998; 85(2):149-52. PubMed ID: 9706309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances: the cytochrome P450 enzymes.
    Slaughter RL; Edwards DJ
    Ann Pharmacother; 1995 Jun; 29(6):619-24. PubMed ID: 7663035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
    Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
    Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
    Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine.
    Davis MP; Homsi J
    Support Care Cancer; 2001 Sep; 9(6):442-51. PubMed ID: 11585271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.
    Ring BJ; Gillespie JS; Binkley SN; Campanale KM; Wrighton SA
    Drug Metab Dispos; 2002 Sep; 30(9):957-61. PubMed ID: 12167559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.